Immune response to an indigenously developed hepatitis-B ( Shanvac-B) vaccine in a tribal community of India

Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed ( Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine Jg. 20; H. 29; S. 3431 - 3435
Hauptverfasser:	Murhekar, M.V, Murhekar, K.M, Arankalle, V.A, Sehgal, S.C
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Oxford Elsevier Ltd 04.10.2002 Elsevier
Schlagworte:	Adolescent Adult Andaman and Nicobar Islands Biological and medical sciences Child Child, Preschool Epidemiology. Vaccinations Female Fundamental and applied biological sciences. Psychology General aspects Hepatitis B Antibodies - blood Hepatitis B Vaccines - adverse effects Hepatitis B Vaccines - immunology Hepatitis-B Hepatitis-B vaccine Humans India Infant Infant, Newborn Infectious diseases Male Medical sciences Microbiology Tribes Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Virology Asia India Hepatitis-B Hepatitis-B vaccine Tribes Andaman and Nicobar Islands India Human Sanitary program Treatment efficiency Vaccination Orthohepadnavirus Hepatic disease Vaccine Cost benefit ratio Infection Virus Viral hepatitis B Hepadnaviridae Viral disease Digestive diseases Community health Safety Hepatitis B virus
ISSN:	0264-410X, 1873-2518
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed ( Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community.
AbstractList	Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed (Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community.Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed (Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community. Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed ( Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community. Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed (Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community. Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed () was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community.
Author	Sehgal, S.C Murhekar, M.V Murhekar, K.M Arankalle, V.A
Author_xml	– sequence: 1 givenname: M.V surname: Murhekar fullname: Murhekar, M.V email: mmurhekar@yahoo.com organization: Regional Medical Research Centre, Indian Council of Medical Research, Post Bag 13, Port Blair 744-101, Andaman and Nicobar Islands, India – sequence: 2 givenname: K.M surname: Murhekar fullname: Murhekar, K.M email: mmurhekar@yahoo.com organization: Regional Medical Research Centre, Indian Council of Medical Research, Post Bag 13, Port Blair 744-101, Andaman and Nicobar Islands, India – sequence: 3 givenname: V.A surname: Arankalle fullname: Arankalle, V.A email: aarankalle@hotmail.com organization: Hepatitis Division, National Institute of Virology, Indian Council of Medical Research, 20-A, Dr. B.R. Ambedkar Road, Pune 411-001, Maharashtra, India – sequence: 4 givenname: S.C surname: Sehgal fullname: Sehgal, S.C email: icmr@cal3.vsnl.net.in, pblicmr@sancharnet.in organization: Regional Medical Research Centre, Indian Council of Medical Research, Post Bag 13, Port Blair 744-101, Andaman and Nicobar Islands, India
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13936451$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12297387$$D View this record in MEDLINE/PubMed
BookMark	eNqNkk1vEzEQhi1URNPCTwD5AkoPC_5Yr9dCqGorPiJV4lCQuFlee5YaNvZibyLl3-M0gUo9EE5zed5Hmpn3BB2FGACh55S8poQ2b24Ia-qqpuTbnLAzQjiXlXyEZrSVvGKCtkdo9hc5Ric5_yCECE7VE3RMGVOSt3KGhsVyuQqAE-Qxhgx4itgE7IPz3yHEVR422MEahjiCw7cwmslPPleXeI5vbk1YG1tdnuEyrC8aH7DBU_KdGbCNW7WfNjj2eFGE5il63Jshw7P9PEVfP7z_cvWpuv78cXF1cV1ZQdRUOUOpZMZKrpSCru2E6RVTXcMMF45ZaUE46ihpOFGOcSGEgrZzhinlZOv4KXq1844p_lpBnvTSZwvDYAKUlbRklHEq64MgbUVNClnA-b9BQYiUTctFQV_s0VW3BKfH5JcmbfSfmxfg5R4w2ZqhTyZYn-85rnhTC1o4seNsijkn6O8Rorcd0Hcd0NsHa8L0XQf01v_2Qc76qbwthikZPxxMn-_SUB609pB0th6CBecT2Em76A8a3j0w2MEHX1b9CZv_yP8Gyxbcog
CODEN	VACCDE
CitedBy_id	crossref_primary_10_1007_s00705_006_0910_0 crossref_primary_10_1016_j_vaccine_2004_05_038 crossref_primary_10_4103_0971_5916_159573 crossref_primary_10_1016_j_trstmh_2008_04_044 crossref_primary_10_1159_000365756 crossref_primary_10_1177_004947550403400227 crossref_primary_10_3748_wjg_v9_i5_1132
Cites_doi	10.1016/S0264-410X(98)00331-4 10.1017/S095026880200691X 10.1002/9780470987131.ch23 10.1046/j.1365-2893.2002.00355.x
ContentType	Journal Article
Copyright	2002 Elsevier Science Ltd 2003 INIST-CNRS
Copyright_xml	– notice: 2002 Elsevier Science Ltd – notice: 2003 INIST-CNRS
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8
DOI	10.1016/S0264-410X(02)00337-7
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE AIDS and Cancer Research Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology
EISSN	1873-2518
EndPage	3435
ExternalDocumentID	12297387 13936451 10_1016_S0264_410X_02_00337_7 S0264410X02003377
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Asia India
GeographicLocations_xml	– name: India
GroupedDBID	--- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACMHX ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADSLC ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGHFR AGQPQ AGUBO AGWPP AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HEJ HLV HMCUK HMG HMK HMO HVGLF HX~ HZ~ IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q38 R2- ROL RPZ SAB SAE SCC SDF SDG SDP SES SEW SIN SNL SPCBC SSH SSI SSZ SVS T5K UKHRP UV1 WH7 WOW WUQ XPP Z5R ZGI ZXP ~G- ~HD 3V. AACTN AAIAV ABLVK ABYKQ AESVU AFCTW AFKWA AJBFU AJOXV AMFUW LCYCR QYZTP RIG 9DU AAYXX AFFHD CITATION AGCQF AGRNS ALIPV IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 PUEGO 7X8
ID	FETCH-LOGICAL-c509t-da1172ac73999eb8b5af929b62a35d2c7ce5d1d106309d235559e8bda299d78d3
ISICitedReferencesCount	11
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000178939100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0264-410X
IngestDate	Wed Oct 01 14:41:25 EDT 2025 Thu Oct 02 05:08:47 EDT 2025 Sun Sep 28 08:48:30 EDT 2025 Wed Feb 19 02:36:06 EST 2025 Mon Jul 21 09:14:58 EDT 2025 Sat Nov 29 05:52:50 EST 2025 Tue Nov 18 21:50:25 EST 2025 Fri Feb 23 02:29:58 EST 2024 Tue Oct 14 19:30:06 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	29
Keywords	Hepatitis-B Hepatitis-B vaccine Tribes Andaman and Nicobar Islands India Human Sanitary program Treatment efficiency Vaccination Orthohepadnavirus Hepatic disease Vaccine Cost benefit ratio Infection Virus Viral hepatitis B Hepadnaviridae Viral disease Digestive diseases Community health Safety Hepatitis B virus
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c509t-da1172ac73999eb8b5af929b62a35d2c7ce5d1d106309d235559e8bda299d78d3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
PMID	12297387
PQID	1500776835
PQPubID	23462
PageCount	5
ParticipantIDs	proquest_miscellaneous_72123174 proquest_miscellaneous_18540317 proquest_miscellaneous_1500776835 pubmed_primary_12297387 pascalfrancis_primary_13936451 crossref_primary_10_1016_S0264_410X_02_00337_7 crossref_citationtrail_10_1016_S0264_410X_02_00337_7 elsevier_sciencedirect_doi_10_1016_S0264_410X_02_00337_7 elsevier_clinicalkey_doi_10_1016_S0264_410X_02_00337_7
PublicationCentury	2000
PublicationDate	2002-10-04
PublicationDateYYYYMMDD	2002-10-04
PublicationDate_xml	– month: 10 year: 2002 text: 2002-10-04 day: 04
PublicationDecade	2000
PublicationPlace	Oxford
PublicationPlace_xml	– name: Oxford – name: Netherlands
PublicationTitle	Vaccine
PublicationTitleAlternate	Vaccine
PublicationYear	2002
Publisher	Elsevier Ltd Elsevier
Publisher_xml	– name: Elsevier Ltd – name: Elsevier
References	Murhekar, Murhekar, Das, Arankalle, Sehgal (BIB1) 2000; 111 Nagaraja Rao, Joshi, Habibullah (BIB5) 1999; 36 M.V. Murhekar, K.M. Murhekar, V.A. Arankalle, S.C. Sehgal SC, Epidemiology of hepatitis-B infection among the Nicobarese: a mongoloid tribe of Andaman and Nicobar Islands, India, Epid Inf 2002;128(3):465–71. Abraham, Mistry, Bapat, Sharma, Reddy, Prasad (BIB4) 1999; 17 Zuckerman JN, Harrison TJ, Zuckerman AJ. Prevention. In: Zuckerman AJ, Thomas HC, editors. Viral hepatitis, 2nd ed, London: Churchill Livingstone. p. 245–52. Kumar, Joshi, Sreenivas, Palan, Nagarjunakumar (BIB3) 1998; 46 Tandon, Irshad, Raju, Mathur, Rao (BIB7) 1991; 93 Murhekar MV, Murhekar MV, Arankalle VA, Sehgal SC. Changing scenario of HAV and HEV exposure among the primitive tribes of Andaman and Nicobar Islands, India over 10-year period, 1989–1999. J Viral Hepatitis 2002;9:315–21. Abraham (10.1016/S0264-410X(02)00337-7_BIB4) 1999; 17 Murhekar (10.1016/S0264-410X(02)00337-7_BIB1) 2000; 111 10.1016/S0264-410X(02)00337-7_BIB8 Kumar (10.1016/S0264-410X(02)00337-7_BIB3) 1998; 46 10.1016/S0264-410X(02)00337-7_BIB6 Tandon (10.1016/S0264-410X(02)00337-7_BIB7) 1991; 93 10.1016/S0264-410X(02)00337-7_BIB2 Nagaraja Rao (10.1016/S0264-410X(02)00337-7_BIB5) 1999; 36
References_xml	– volume: 111 start-page: 199 year: 2000 end-page: 203 ident: BIB1 article-title: Prevalence of hepatitis-B infection among the primitive tribes of Andaman: prevalence of hepatitis-B infection among the primitive tribes of Andaman & Nicobar Islands publication-title: Indian J. Med. Res. – reference: Murhekar MV, Murhekar MV, Arankalle VA, Sehgal SC. Changing scenario of HAV and HEV exposure among the primitive tribes of Andaman and Nicobar Islands, India over 10-year period, 1989–1999. J Viral Hepatitis 2002;9:315–21. – reference: M.V. Murhekar, K.M. Murhekar, V.A. Arankalle, S.C. Sehgal SC, Epidemiology of hepatitis-B infection among the Nicobarese: a mongoloid tribe of Andaman and Nicobar Islands, India, Epid Inf 2002;128(3):465–71. – reference: Zuckerman JN, Harrison TJ, Zuckerman AJ. Prevention. In: Zuckerman AJ, Thomas HC, editors. Viral hepatitis, 2nd ed, London: Churchill Livingstone. p. 245–52. – volume: 36 start-page: 581 year: 1999 end-page: 583 ident: BIB5 article-title: Immunogenecity of a low dose of indigenously developed recombinant hepatitis-B vaccine in neonates and infants publication-title: Indian Pediatr. – volume: 93 start-page: 337 year: 1991 end-page: 339 ident: BIB7 article-title: Prevalence of HBsAg and anti-HBs in children and strategy suggested for immunization in India publication-title: Indian J. Med. Res. – volume: 46 start-page: 620 year: 1998 end-page: 622 ident: BIB3 article-title: Clinical safety and efficacy of first indigenous recombinant hepatitis-B vaccine publication-title: J. Assoc. Phys. Ind. – volume: 17 start-page: 1125 year: 1999 end-page: 1129 ident: BIB4 article-title: Evaluation of a new recombinant DNA hepatitis-B vaccine ( publication-title: Vaccine – volume: 46 start-page: 620 year: 1998 ident: 10.1016/S0264-410X(02)00337-7_BIB3 article-title: Clinical safety and efficacy of first indigenous recombinant hepatitis-B vaccine publication-title: J. Assoc. Phys. Ind. – volume: 17 start-page: 1125 year: 1999 ident: 10.1016/S0264-410X(02)00337-7_BIB4 article-title: Evaluation of a new recombinant DNA hepatitis-B vaccine (Shanvac-B) publication-title: Vaccine doi: 10.1016/S0264-410X(98)00331-4 – volume: 111 start-page: 199 year: 2000 ident: 10.1016/S0264-410X(02)00337-7_BIB1 article-title: Prevalence of hepatitis-B infection among the primitive tribes of Andaman: prevalence of hepatitis-B infection among the primitive tribes of Andaman & Nicobar Islands publication-title: Indian J. Med. Res. – volume: 36 start-page: 581 year: 1999 ident: 10.1016/S0264-410X(02)00337-7_BIB5 article-title: Immunogenecity of a low dose of indigenously developed recombinant hepatitis-B vaccine in neonates and infants publication-title: Indian Pediatr. – ident: 10.1016/S0264-410X(02)00337-7_BIB2 doi: 10.1017/S095026880200691X – volume: 93 start-page: 337 year: 1991 ident: 10.1016/S0264-410X(02)00337-7_BIB7 article-title: Prevalence of HBsAg and anti-HBs in children and strategy suggested for immunization in India publication-title: Indian J. Med. Res. – ident: 10.1016/S0264-410X(02)00337-7_BIB6 doi: 10.1002/9780470987131.ch23 – ident: 10.1016/S0264-410X(02)00337-7_BIB8 doi: 10.1046/j.1365-2893.2002.00355.x
SSID	ssj0005319
Score	1.7344518
Snippet	Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using...
SourceID	proquest pubmed pascalfrancis crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	3431
SubjectTerms	Adolescent Adult Andaman and Nicobar Islands Biological and medical sciences Child Child, Preschool Epidemiology. Vaccinations Female Fundamental and applied biological sciences. Psychology General aspects Hepatitis B Antibodies - blood Hepatitis B Vaccines - adverse effects Hepatitis B Vaccines - immunology Hepatitis-B Hepatitis-B vaccine Humans India Infant Infant, Newborn Infectious diseases Male Medical sciences Microbiology Tribes Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Virology
Title	Immune response to an indigenously developed hepatitis-B ( Shanvac-B) vaccine in a tribal community of India
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X02003377 https://dx.doi.org/10.1016/S0264-410X(02)00337-7 https://www.ncbi.nlm.nih.gov/pubmed/12297387 https://www.proquest.com/docview/1500776835 https://www.proquest.com/docview/18540317 https://www.proquest.com/docview/72123174
Volume	20
WOSCitedRecordID	wos000178939100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 20091019 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M7P dateStart: 20020101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central - New (Subscription) customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Consumer Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0R dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLYmBggJISi3chlGQtMmlpI4SZ08dlNhaF2puq7qW-TErjYxZdNWpu3X8Fc5x47jgKg2Hng5SqKcJur5Yn8-PhdCPsThnEeSSW-eq7kXJXngpXkReExI5atUJaHUicIDPhwms1k6Wln5aXNhLk94WSZXV-nZfzU1XANjY-rsP5i7_lG4AMdgdJBgdpC3MvxXzPjAZig6-FV3xhAYzmjrsZ5c20wp4JpHCiOqF8cX3jZyzYMjUV6KwttGZwEc4K47ekTER2yMpUuJ6HySRZWCIo9Fk91OjUZtxMPxbn-vp0Mt9jsunLZ5fa_j_LG9cW-41xsMdIDmtOPcrAf93S-9gXbUdiq3rnVUMB3y5hyVNoOmMcABGfOiwJ81R2PmN1DHUrtrY4bXMKqmDGVP479OA8YjcVA_AP5ALDSLXtuQe9zNfXa__48psQ5UBH6M-7SwvF5lPE5x2OTjqYshCnXnmPo5LkXsk3v4hs82qwcvIz8Pz8QFfJJz00tl-WJHk57JY_KoWq3QnkHZE7Kiyha5Z_qXXrfI_f0qMqNF1kemBvr1Fp24lL6LLbpOR646Oui0phiApbPAqVV_Sr4b1FKLWro4paKkTdTSGrW0gVq6UWN2k1aIBTUqqEEsrRFLT-dUI_YZOfzcn-zselUfEK8AOrvwpAiAZouCA5lOVZ7ksZgDq8-7TISxZAUvVCwDGWD5uFQyYNAxDDK5FEC1JE9k-JzcKU9L9ZLQIpBxmHcD5bMiEioSoQJrSb_oym43TUWbRNZAWVEVycdeLSeZi4YEu2Zo18xnmbZrxtukU6udmSoxNyl0rfUzmwINk3YGAL5JMakVK45suO9tVNd-g5l70wrkbfLe4i6DSQZ3DkWpwMQZrBqx7Bes1trk3bJ7Elj8wWpk-R0caXLAozZ5YUDt3oBhC72Ev7rpFV-TB25oeUPuLM5_qLfkbnEJkDtf0x8nyhnXMgGZ7ARrZHW7PxyN4WzfN3KCkn1DyUe_AMMODD8
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immune+response+to+an+indigenously+developed+hepatitis-B+%28Shanvac-B%29+vaccine+in+a+tribal+community+of+India&rft.jtitle=Vaccine&rft.au=MURHEKAR%2C+M.+V&rft.au=MURHEKAR%2C+K.+M&rft.au=ARANKALLE%2C+V.+A&rft.au=SEHGAL%2C+S.+C&rft.date=2002-10-04&rft.pub=Elsevier&rft.issn=0264-410X&rft.volume=20&rft.issue=29-30&rft.spage=3431&rft.epage=3435&rft_id=info:doi/10.1016%2FS0264-410X%2802%2900337-7&rft.externalDBID=n%2Fa&rft.externalDocID=13936451
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon